SURVYR

GMED

Globus Medical, Inc.
$80.90
−$0.93 (1.14%)Oct 27 close
Health CareS&P 400 CompareTechnicals
1M3M6M1Y2Y
-7%+8%+23%+38%+53%Oct 2025Oct 2026Apr 202652w low $59.51
GMEDSPY
Wall St. Highest PT $125.00 (+54.5%) Wall St. Avg PT $100.92 (+24.8%)
$60$79$98$117$136POC $88Hi $125Avg $101
Underwater Drawdown %Max DD -24.3%Current -16.4%
0.0%-24.3%
Relative Strength vs SPY+14.4% vs SPYOutperforming
+60%0%-60%
1W
+$1.94 (2.46%)
1M
+$6.38 (8.56%)
3M
+$0.32 (0.40%)
6M
−$9.84 (10.84%)
YTD
−$6.41 (7.34%)
1Y
+$17.64 (27.88%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
13 analysts · mean score 1.79
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$80.90
Average target$100.92
+$20.02 (+24.8%) upsideaverage target vs current price
CurrentAverageMedian
Low$84.00
Median$100.92
High$125.00
12-month Wall Street target range

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$10.6B
P/E (last 12 months)20.2
P/E (next 12 months, estimated)14.6
52-week range$59.51 – $101.40
Revenue growth (latest quarter vs a year ago)+5.9%
Dividend yieldNo dividend
Analyst consensusBuy (13)
Average analyst price target$100.92 (+25%)

What they do

Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation.

Healthcare · Medical Devices
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
57th percentile in sector
B-
12-1 return: +24.0%
Percentile within its GICS sector across the S&P 1500.
Growth
36th percentile in sector
C-
Revenue growth (YoY): +5.9%
Percentile within its GICS sector across the S&P 1500.
Value
75th percentile in sector
B+
Forward E/P: 7.0% · EBITDA/EV: 10.3%
Percentile within its GICS sector across the S&P 1500.
Profitability
65th percentile in sector
B
Profit margin: +17.0% · Return on equity: +11.8%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

GMED earningsNext report in 9 days
Next report · quarter Sep 2026
Thu Nov 5, 2026After the close
EPS consensus$1.20
Revenue consensus–
Last 4 quarters · EPS vs estimate
Aug 6, 2026$1.34est $1.10+21.9%Above estimates
May 7, 2026$1.12est $0.92+21.7%Above estimates
Feb 24, 2026$1.28est $1.15+11.0%Above estimates
Nov 6, 2025$1.18est $0.78+51.1%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-27 18:17:57 ET
24-1125-0225-0525-0825-1126-0226-0526-080.001.34
EstimateActual (beat)Actual (miss)

News & catalysts

More news
DaVita Stock Gains 55.6% Year to Date: What's Behind the Rally?
Zacks · Oct 22
Kuehn Law Encourages Investors of Globus Medical, Inc. to Contact Law Firm
PR Newswire · Oct 21
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now
Zacks · Oct 09
10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research
Zacks · Oct 08
Insider trades
Tobin James R
Director · 2026-09-15
Sell
$2.2M
Zarrilli Stephen T
Director · 2026-08-18
Sell
$2.2M
None
None · None
Sell
–

Stats refreshed 2026-10-27 18:17:57 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026